Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RedHill Biopharma Ltd.

www.redhillbio.com

Latest From RedHill Biopharma Ltd.

Finance Watch: Coronavirus-Related Stock Market Meltdown Didn’t Stop Passage Bio IPO

Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23.3% at $22.20 but fell to $21.50 when stocks recovered on 2 March. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz.

Financing Gene Therapy

Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies

Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.

Deals Business Strategies

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

Deals Gastrointestinal

Keeping Track: Biosimilars, Novel Approvals, And Ebola

The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • RedHill Biopharma Ltd.
  • Senior Management
  • Dror Ben-Asher, CEO
    Micha Ben Chorin, CFO
    Adi Frish, SVP, Bus. Dev & Licensing
    Reza Fathi , PhD, SVP, R&D
    Gilead Raday, COO
    June S Almenoff, MD, PhD, CSO
    Guy Goldberg, CBO
  • Contact Info
  • RedHill Biopharma Ltd.
    Phone: (972) 3 541 3131
    21 Ha’arba’a St.
    Tel-Aviv, 64739
    Israel
UsernamePublicRestriction

Register